KRAS and pancreatic neoplasm: Recent evidence showed that several genetic mutations, including K-Ras, TP53, SMAD family member 4 (SMAD4), and cyclin dependent kinase inhibitor 2A/P16 (CDKN2A/P16), drove the oncogenesis of pancreatic cancer (46).